Advertisement


Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Advertisement